↓ Skip to main content

Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks

Overview of attention for article published in BMC Medicine, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
13 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
132 Dimensions

Readers on

mendeley
202 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks
Published in
BMC Medicine, March 2015
DOI 10.1186/s12916-015-0285-8
Pubmed ID
Authors

Carmelo Scarpignato, Angel Lanas, Corrado Blandizzi, Willem F Lems, Matthias Hermann, Richard H Hunt

Abstract

There are several guidelines addressing the issues around the use of NSAIDs. However, none has specifically addressed the upper versus lower gastrointestinal (GI) risk of COX-2 selective and non-selective compounds nor the interaction at both the GI and cardiovascular (CV) level of either class of drugs with low-dose aspirin. This Consensus paper aims to develop statements and guidance devoted to these specific issues through a review of current evidence by a multidisciplinary group of experts. A modified Delphi consensus process was adopted to determine the level of agreement with each statement and to determine the level of agreement with the strength of evidence to be assigned to the statement. For patients with both low GI and CV risks, any non-selective NSAID (ns-NSAID) alone may be acceptable. For those with low GI and high CV risk, naproxen may be preferred because of its potential lower CV risk compared with other ns-NSAIDs or COX-2 selective inhibitors, but celecoxib at the lowest approved dose (200 mg once daily) may be acceptable. In patients with high GI risk, if CV risk is low, a COX-2 selective inhibitor alone or ns-NSAID with a proton pump inhibitor appears to offer similar protection from upper GI events. However, only celecoxib will reduce mucosal harm throughout the entire GI tract. When both GI and CV risks are high, the optimal strategy is to avoid NSAID therapy, if at all possible. Time is now ripe for offering patients with osteoarthritis the safest and most cost-effective therapeutic option, thus preventing serious adverse events which could have important quality of life and resource use implications.

Twitter Demographics

The data shown below were collected from the profiles of 13 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 202 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
Argentina 1 <1%
Unknown 199 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 31 15%
Researcher 25 12%
Student > Master 24 12%
Student > Doctoral Student 19 9%
Other 17 8%
Other 53 26%
Unknown 33 16%
Readers by discipline Count As %
Medicine and Dentistry 82 41%
Pharmacology, Toxicology and Pharmaceutical Science 30 15%
Agricultural and Biological Sciences 12 6%
Biochemistry, Genetics and Molecular Biology 9 4%
Nursing and Health Professions 8 4%
Other 21 10%
Unknown 40 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2020.
All research outputs
#1,142,547
of 18,209,496 outputs
Outputs from BMC Medicine
#884
of 2,774 outputs
Outputs of similar age
#18,311
of 230,256 outputs
Outputs of similar age from BMC Medicine
#1
of 1 outputs
Altmetric has tracked 18,209,496 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,774 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 230,256 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them